Favorable Media Coverage Somewhat Unlikely to Affect Magellan Health (MGLN) Share Price

Headlines about Magellan Health (NASDAQ:MGLN) have been trending positive on Monday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Magellan Health earned a news impact score of 0.27 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.5810310426154 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

Magellan Health stock opened at $108.45 on Monday. The company has a market cap of $2,675.38, a price-to-earnings ratio of 19.72, a price-to-earnings-growth ratio of 1.15 and a beta of 0.50. Magellan Health has a 52-week low of $67.20 and a 52-week high of $111.10. The company has a current ratio of 1.66, a quick ratio of 1.62 and a debt-to-equity ratio of 0.58.

Magellan Health (NASDAQ:MGLN) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.29 by $0.26. The firm had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.62 billion. Magellan Health had a return on equity of 10.86% and a net margin of 1.89%. The company’s revenue for the quarter was up 34.1% compared to the same quarter last year. During the same period in the prior year, the business earned $1.80 EPS. sell-side analysts forecast that Magellan Health will post 6.32 EPS for the current year.

A number of analysts have weighed in on the stock. ValuEngine raised shares of Magellan Health from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 6th. Zacks Investment Research raised shares of Magellan Health from a “hold” rating to a “buy” rating and set a $118.00 target price for the company in a research report on Thursday, March 22nd. BidaskClub raised shares of Magellan Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 17th. Finally, Leerink Swann upgraded Magellan Health from a “market perform” rating to an “outperform” rating in a report on Thursday, March 15th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $97.50.

In other Magellan Health news, CEO Mostafa Kamal sold 15,428 shares of the stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $99.04, for a total transaction of $1,527,989.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Barry M. Smith sold 13,375 shares of the stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $103.52, for a total value of $1,384,580.00. Following the transaction, the chief executive officer now owns 57,605 shares in the company, valued at $5,963,269.60. The disclosure for this sale can be found here. Insiders have sold a total of 78,428 shares of company stock worth $7,858,688 over the last 90 days. Company insiders own 3.60% of the company’s stock.

WARNING: This piece of content was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/04/16/favorable-media-coverage-somewhat-unlikely-to-affect-magellan-health-mgln-share-price.html.

Magellan Health Company Profile

Magellan Health, Inc provides healthcare management services in the United States. It operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine for health plans, care organizations, and employers.

Insider Buying and Selling by Quarter for Magellan Health (NASDAQ:MGLN)

Receive News & Ratings for Magellan Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply